United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction on Friday, January 13th. The shares were sold at an average price of $261.52, for a total transaction of $2,092,160.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $33,997.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

United Therapeutics Trading Down 0.6 %

United Therapeutics stock traded down $1.54 during trading hours on Wednesday, reaching $259.56. The stock had a trading volume of 286,221 shares, compared to its average volume of 401,356. The stock has a market cap of $11.83 billion, a PE ratio of 17.65, a PEG ratio of 1.54 and a beta of 0.62. United Therapeutics Co. has a 52 week low of $158.38 and a 52 week high of $283.09. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39. The company has a fifty day simple moving average of $270.88 and a 200-day simple moving average of $240.79.

United Therapeutics (NASDAQ:UTHR – Get Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.57 by $1.34. The business had revenue of $516.00 million for the quarter, compared to analyst estimates of $492.92 million. United Therapeutics had a net margin of 38.03% and a return on equity of 16.63%. Analysts forecast that United Therapeutics Co. will post 16.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in UTHR. Wellington Management Group LLP boosted its stake in shares of United Therapeutics by 73.7% during the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company's stock valued at $300,585,000 after purchasing an additional 710,668 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of United Therapeutics by 205.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 641,656 shares of the biotechnology company's stock valued at $151,200,000 after purchasing an additional 431,739 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of United Therapeutics by 1,011.5% during the 2nd quarter. Deutsche Bank AG now owns 196,876 shares of the biotechnology company's stock valued at $46,393,000 after purchasing an additional 179,163 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of United Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,411,616 shares of the biotechnology company's stock valued at $923,703,000 after purchasing an additional 163,542 shares in the last quarter. Finally, Farallon Capital Management LLC boosted its stake in shares of United Therapeutics by 40.0% during the 3rd quarter. Farallon Capital Management LLC now owns 549,673 shares of the biotechnology company's stock valued at $115,091,000 after purchasing an additional 156,977 shares in the last quarter. Institutional investors own 95.63% of the company's stock.

About United Therapeutics

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Stories

• Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
• What does Nu Holdings Stock Have To Do With Warren Buffett?
• J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
• Is Intel Stock On The Verge Of Breaking Out?
• Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
• Can Alaska Air Continue Soaring Above The Airline Industry?

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.